Active Ingredient History

  • Now
Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation. Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.   Wikipedia

  • SMILES: C1CN2CC[C@]3(C2)Cc4ncccc4O[C@@H]13
  • Mol. Mass: 216.28
  • ALogP: 1.48
  • ChEMBL Molecule:
More Chemistry
5a,6,9,10-tetrahydro-7h,11h-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine | dianicline | ssr591813 | ssr 591813 | ssr-591813


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue